GlassScriptPhysician profile
John Virgil Borders
NPI 1962401026
$8,236.25
in general payments reported to CMS, 2019-2025
56 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $891 · 2021: $919 · 2022: $1,206 · 2023: $1,460 · 2024: $1,282 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,984 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,983.97 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $834.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $705.12 | 2019-2024 | |
| Lilly USA, LLC | $580.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $516.35 | 2019-2025 | |
| Amgen INC. | $506.05 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $432.11 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $408.77 | 2019-2025 | Ubrelvy |
| Astellas Pharma US INC | $361.77 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $294.48 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.53 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $241.90 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $231.03 | 2023-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $225.90 | 2020-2025 | Nexletol |
| Almatica Pharma LLC | $215.43 | 2023-2025 | Loreev Xr, Gralise |
| Bayer Healthcare Pharmaceuticals INC. | $215.42 | 2021-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $143.42 | 2019-2024 | Airsupra |
| Axsome Therapeutics, INC. | $136.69 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $127.23 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.92 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $115.29 | 2019-2025 | Rexulti |
| Seqirus USA INC | $101.41 | 2019-2025 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Amarin Pharma, INC. | $100.22 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $99.57 | 2020-2023 | Verquvo, Belsomra |
| Supernus Pharmaceuticals, INC. | $81.22 | 2019-2022 | |
| Lundbeck LLC | $77.25 | 2023-2024 | Vyepti, Rexulti |
| Idorsia Pharmaceuticals US INC | $76.90 | 2022-2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $75.43 | 2019-2021 | |
| Eisai INC. | $74.20 | 2021-2025 | |
| Azurity Pharmaceuticals, INC. | $68.88 | 2023-2025 | Horizant, Horizant |
| Sunovion Pharmaceuticals INC. | $65.75 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $64.18 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $63.53 | 2024 | Voquezna |
| Medicure Pharma INC. | $61.47 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $59.83 | 2022-2023 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $55.97 | 2019-2023 | Seglentis |
| Corcept Therapeutics | $38.55 | 2025 | Korlym |
| Currax Pharmaceuticals LLC | $36.89 | 2020-2023 | Nexletol |
| Atricure, INC. | $33.77 | 2024-2025 | Atriclip Laa Exclusion System |
| Abbott Laboratories | $31.79 | 2022-2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $30.45 | 2024-2025 | Austedo Xr, Austedo Xr |
| Ultragenyx Pharmaceutical INC. | $28.83 | 2022 | |
| Acorda Therapeutics, INC | $25.91 | 2019-2020 | |
| Aytu Biopharma, INC. | $24.99 | 2019 | |
| Allergan, INC. | $23.71 | 2019 | |
| Vanda Pharmaceuticals INC. | $23.53 | 2025 | Fanapt |
| Alexion Pharmaceuticals, INC. | $22.39 | 2021 | |
| Amneal Pharmaceuticals LLC | $18.84 | 2025 | Unithroid |
| Antares Pharma, INC. | $18.46 | 2021 | |
| Medtronic USA, INC. | $16.96 | 2019 | |
| Daiichi Sankyo INC. | $16.77 | 2022 | |
| Dexcom, INC. | $15.11 | 2024 | Dexcom G6 Transmitter |
| Evoke Pharma, INC. | $14.96 | 2023 | Gimoti |
| Biogen, INC. | $14.93 | 2024 | Leqembi |
| Inspire Medical Systems, INC. | $13.27 | 2024 | Inspire |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Borders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.